{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"74.5","upperLimit":"85.3","value":"80.5"},{"groupId":"OG001","lowerLimit":"75.8","upperLimit":"86.4","value":"81.8"}]}],"title":"12 Months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"49.9","upperLimit":"63.4","value":"57.0"},{"groupId":"OG001","lowerLimit":"56.6","upperLimit":"69.8","value":"63.6"}]}],"title":"24 Months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"36.0","upperLimit":"49.6","value":"42.9"},{"groupId":"OG001","lowerLimit":"41.4","upperLimit":"55.3","value":"48.5"}]}],"title":"36 Months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"31.2","upperLimit":"44.7","value":"38.0"},{"groupId":"OG001","lowerLimit":"34.6","upperLimit":"48.5","value":"41.6"}]}],"title":"48 Months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"216"},{"groupId":"OG001","value":"213"}],"units":"Participants"}],"description":"Overall survival was defined as the time from the date of randomization to the date of death from any cause. If a patient was not known to have died, survival was censored at the date of last contact. Kaplan-Meier methodology was used to estimate the median overall survival for each treatment group.","dispersionType":"95% Confidence Interval","groups":[{"description":"Everolimus was administered in accordance with a 10-mg daily dosing regimen (two 5-mg tablets) in conjunction with octreotide 30 mg intramuscularly (i.m.) every 28 days. Patients were treated until progression or unacceptable toxicity. Each treatment cycle lasted 28 days. Patients received their first dose of everolimus at Cycle 1, Day 1. Administration of octreotide was performed every 28 days (± 4 days) starting on Cycle 1, Day 1.","id":"OG000","title":"Octreotide+ Everolimus"},{"description":"Matching placebo was administered in accordance with a 10-mg daily dosing regimen (two 5-mg tablets) in conjunction with octreotide 30 mg intramuscularly (i.m.) every 28 days. Patients were treated until progression or unacceptable toxicity; Each treatment cycle lasted 28 days. Patients received their first dose of matching placebo at Cycle 1, Day 1. Administration of octreotide was performed every 28 days (± 4 days) starting on Cycle 1 Day 1. Open Label - Patients who had progressive disease in this arm, can move to the open label Everolimus + depot octreotide by choice.","id":"OG001","title":"Octreotide+ Placebo Followed by Open Label Arm"}],"paramType":"NUMBER","populationDescription":"The Full Analysis Set (FAS; Intent-to-treat Population) consists of all randomized patients.","reportingStatus":"POSTED","timeFrame":"Months 12, 24, 36, 48","title":"Overall Survival Using Kaplan-Meier Methodology","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}